Regeneron Pharmaceuticals (REGN)

266.97 +2.31  +0.87%  May 17, 8:00PM
Add to Watchlists Create an Alert

Regeneron Pharmaceuticals R&D Expense Quarterly:

180.30M for March 31, 2013
View Full Chart

Regeneron Pharmaceuticals R&D Expense Quarterly Chart

    Regeneron Pharmaceuticals Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 2   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    March 31, 2013 180.30M
    Dec. 31, 2012 181.02M
    Sept. 30, 2012 158.30M
    June 30, 2012 147.37M
    March 31, 2012 138.86M
    Dec. 31, 2011 129.04M
    Sept. 30, 2011 127.92M
    June 30, 2011 143.15M
    March 31, 2011 129.39M
    Dec. 31, 2010 125.21M
    Sept. 30, 2010 122.04M
    June 30, 2010 124.53M
    March 31, 2010 117.47M
    Dec. 31, 2009 118.79M
    Sept. 30, 2009 105.43M
    June 30, 2009 94.23M
    March 31, 2009 80.31M
    Dec. 31, 2008 73.20M
    Sept. 30, 2008 73.86M
    June 30, 2008 66.78M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
       
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro
    June 30, 2003 Go Pro
    March 31, 2003 Go Pro
    Dec. 31, 2002 Go Pro
    Sept. 30, 2002 Go Pro
    June 30, 2002 Go Pro
    March 31, 2002 Go Pro
    Dec. 31, 2001 Go Pro
    Sept. 30, 2001 Go Pro
    June 30, 2001 Go Pro
    March 31, 2001 Go Pro
    Dec. 31, 2000 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    REGN R&D Expense Quarterly Benchmarks

    Companies
    Celgene Corporation 452.40M
    Biogen Idec 284.34M
    Sanofi 1.480B

    REGN R&D Expense Quarterly Rankings

    Overall 98th percentile
    90 of 7593
    Sector 96th percentile
    25 of 650 in Healthcare
    Industry 96th percentile
    8 of 237 in Biotechnology

    REGN R&D Expense Quarterly Range, Past 5 Years

    Minimum 66.78M Jun 2008
    Maximum 181.02M Dec 2012
    Average 121.86M